High-density single nucleotide polymorphism array analysis and ASXL1 gene mutation screening in chronic myeloid leukemia during disease progression

No abstract is available for this paper.

• Publication year

  2010

• Venue

  Leukemia

• Publication date

  2010-04-22

• Fields of study

  Biology, Medicine

• Identifiers
  DOI 10.1038/leu.2010.65PMID 20410925
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

  2010cited by this paper
• Mutations of polycomb‐associated gene ASXL1 in myelodysplastic syndromes and chronic myelomonocytic leukaemia

  2009cited by this paper
• Six-year follow-up of patients receiving imatinib for the first-line treatment of chronic myeloid leukemia

  2009cited by this paper
• Mutations of ASXL1 gene in myeloproliferative neoplasms

  2009cited by this paper
• SOX7, down-regulated in colorectal cancer, induces apoptosis and inhibits proliferation of colorectal cancer cells.

  2009cited by this paper
• Imatinib resistance in CML.

  2009cited by this paper
• Sox7 Is an Independent Checkpoint for β-Catenin Function in Prostate and Colon Epithelial Cells

  2008cited by this paper
• Variable breakpoints target PAX5 in patients with dicentric chromosomes: A model for the basis of unbalanced translocations in cancer

  2008cited by this paper
• Genome-wide analysis of copy number changes and loss of heterozygosity in myelodysplastic syndrome with del(5q) using high-density single nucleotide polymorphism arrays

  2008cited by this paper
• BCR–ABL1 lymphoblastic leukaemia is characterized by the deletion of Ikaros

  2008cited by this paper
• CXCR4 up-regulation by imatinib induces chronic myelogenous leukemia (CML) cell migration to bone marrow stroma and promotes survival of quiescent CML cells

  2008cited by this paper
• Zinc and its transporter ZIP10 are involved in invasive behavior of breast cancer cells

  2007cited by this paper
• Drp1 Mediates Caspase-Independent Type III Cell Death in Normal and Leukemic Cells

  2007cited by this paper
• Impact of mutant p53 functional properties on TP53 mutation patterns and tumor phenotype: lessons from recent developments in the IARC TP53 database

  2007cited by this paper
• Prevalence and prognostic significance of allelic imbalance by single-nucleotide polymorphism analysis in low-risk myelodysplastic syndromes.

  2007cited by this paper
• Genomewide screening of DNA copy number changes in chronic myelogenous leukemia with the use of high‐resolution array‐based comparative genomic hybridization

  2006cited by this paper
• hTERT, the catalytic component of telomerase, is downregulated in the haematopoietic stem cells of patients with chronic myeloid leukaemia

  2006cited by this paper
• Characterization of Asxl1, a murine homolog of Additional sex combs, and analysis of the Asx-like gene family.

  2006cited by this paper
• Extended tracts of homozygosity in outbred human populations.

  2006cited by this paper
• Association between acquired uniparental disomy and homozygous gene mutation in acute myeloid leukemias.

  2005cited by this paper
• Genome-wide single nucleotide polymorphism analysis reveals frequent partial uniparental disomy due to somatic recombination in acute myeloid leukemias.

  2005cited by this paper
• p210BCR-ABL inhibits SDF-1 chemotactic response via alteration of CXCR4 signaling and down-regulation of CXCR4 expression.

  2005cited by this paper
• Control of DNA replication and its potential clinical exploitation

  2005cited by this paper
• Isolation and analysis of candidate myeloid tumor suppressor genes from a commonly deleted segment of 7q22.

  2005cited by this paper
• The biology of CML blast crisis.

  2004cited by this paper
• NRAS, FLT3 and TP53 mutations in patients with myelodysplastic syndrome and a del(5q).

  2004cited by this paper
• MASL1, a candidate oncogene found in amplification at 8p23.1, is translocated in immunoblastic B-cell lymphoma cell line OCI-LY8

  2004cited by this paper
• Frequency of major molecular responses to imatinib or interferon alfa plus cytarabine in newly diagnosed chronic myeloid leukemia.

  2003cited by this paper
• Genomic imbalances in CML blast crisis: 8q24.12–q24.13 Segment identified as a common region of over‐representation

  2003cited by this paper
• Immunohistochemical localization of plakophilins (PKP1, PKP2, PKP3, and p0071) in primary oropharyngeal tumors: correlation with clinical parameters.

  2003cited by this paper
• Cytogenetic and Molecular Genetic Evolution of Chronic Myeloid Leukemia

  2002cited by this paper
• Chronic myelogenous leukemia: mechanisms underlying disease progression

  2002cited by this paper
• Serial monitoring of BCR–ABL by peripheral blood real‐time polymerase chain reaction predicts the marrow cytogenetic response to imatinib mesylate in chronic myeloid leukaemia

  2002cited by this paper
• Activity of a specific inhibitor of the BCR-ABL tyrosine kinase in the blast crisis of chronic myeloid leukemia and acute lymphoblastic leukemia with the Philadelphia chromosome.

  2001cited by this paper
• Telomere length shortening in chronic myelogenous leukemia is associated with reduced time to accelerated phase.

  2000cited by this paper
• Desmosomal plakophilin 2 as a differentiation marker in normal and malignant tissues.

  1999cited by this paper
• Identification of a novel gene, MASL1, within an amplicon at 8p23.1 detected in malignant fibrous histiocytomas by comparative genomic hybridization.

  1999cited by this paper
• A novel amplicon at 8p22-23 results in overexpression of cathepsin B in esophageal adenocarcinoma.

  1998cited by this paper
• Prognostic significance of cathepsins B and L in primary human breast cancer.

  1998cited by this paper
• Hematology, Basic Principles and Practice, 2nd ed

  1995cited by this paper
• Hematology: Basic Principles and Practice, 2nd ed

  1995cited by this paper
• Alterations in the p53 gene and the clonal evolution of the blast crisis of chronic myelocytic leukemia.

  1989cited by this paper
• A New Consistent Chromosomal Abnormality in Chronic Myelogenous Leukaemia identified by Quinacrine Fluorescence and Giemsa Staining

  1973cited by this paper

• Concomitant T315I and E459K mutations in chronic myeloid leukemia: A case report

  2025cites this paper
• The role of ASXL1 mutations and ASXL1 CircRNAs in cancer

  2024cites this paper
• ASXL1 MUTATION ANALYSIS IN CHRONIC MYELOID LEUKAEMIA PATIENTS

  2023cites this paper
• Frequency and prognostic influence of ASXL1 mutations and its potential association with BCR-ABL1 transcript type and smoke in chronic myeloid leukemia patients.

  2023cites this paper
• The association of genetic alterations with response rate in newly diagnosed chronic myeloid leukemia patients.

  2022cites this paper
• The characteristics and clinical prognosis analysis of ASXL1 mutations in Chinese adult patients with primary cytogenetically normal acute myeloid leukemia by next-generation sequencing

  2022cites this paper
• Association of DNA repair gene XPC Ala499Val (rs2228000 C>T) and Lys939Gln (rs2228001 A>C) polymorphisms with the risk of chronic myeloid leukemia: A case–control study in a South Indian population

  2021cites this paper
• Detection of an Insertion in the ATXN3 Gene in Chronic Myeloid Leukemia Cases Using Exome Sequencing

  2021cites this paper
• Reducing hyperactivated BAP1 attenuates mutant ASXL1-driven myeloid malignancies in human haematopoietic cells.

  2021cites this paper
• Mutational landscape of chronic myeloid leukemia: more than a single oncogene leukemia

  2021cites this paper
• The Functions and Mechanisms of PR-DUB in Malignancy

  2021cites this paper
• Murine Models of Myelofibrosis

  2020cites this paper
• Mutation accumulation in cancer genes relates to nonoptimal outcome in chronic myeloid leukemia.

  2020cites this paper
• Detection of an Insertion in the ATXN3 Gene in CML Cases Using Exome Sequencing

  2020cites this paper
• A Case of Tyrosine Kinase Inhibitor-Resistant Chronic Myeloid Leukemia, Chronic Phase with ASXL1 Mutation

  2020cites this paper
• The Association of rs2114358 in the miR-1206 Polymorphism to Chronic Myeloid Leukemia.

  2019cites this paper
• TET2 rs2454206, TET2 rs12498609 and ASXL1 rs3746609 single nucleotide polymorphisms in patients with myelodysplastic syndromes.

  2019cites this paper
• Low prevalence of the BCR–ABL1 fusion gene in a normal population in southern Sarawak

  2019cites this paper
• Druggable Biochemical Pathways and Potential Therapeutic Alternatives to Target Leukemic Stem Cells and Eliminate the Residual Disease in Chronic Myeloid Leukemia

  2019cites this paper
• RUNX1 mutations promote leukemogenesis of myeloid malignancies in ASXL1-mutated leukemia

  2019cites this paper
• Epigenetic Reprogramming and Emerging Epigenetic Therapies in CML

  2019cites this paper
• Evidence that 6q25.1 variant rs6931104 confers susceptibility to chronic myeloid leukemia through RMND1 regulation

  2019cites this paper
• Laying the foundation for genomically-based risk assessment in chronic myeloid leukemia

  2019cites this paper
• Disruption of asxl1 results in myeloproliferative neoplasms in zebrafish

  2019cites this paper
• De novo UBE2A mutations are recurrently acquired during chronic myeloid leukemia progression and interfere with myeloid differentiation pathways

  2019cites this paper
• Clonal Hematopoiesis with Oncogenic Potential (CHOP): Separation from CHIP and Roads to AML

  2019cites this paper
• ASXL1 alteration cooperates with JAK2V617F to accelerate myelofibrosis

  2019cites this paper
• Systematic review of pre-clinical chronic myeloid leukaemia

  2018cites this paper
• Molecular Oncology Testing for Cancer Diagnosis, Prognosis, and Treatment Decisions

  2018cites this paper
• Frequent ASXL1 mutations in children and young adults with chronic myeloid leukemia

  2018cites this paper
• ASXL2 regulates hematopoiesis in mice and its deficiency promotes myeloid expansion

  2018cites this paper
• Assessing copy number aberrations and copy neutral loss of heterozygosity across the genome as best practice: An evidence based review of clinical utility from the cancer genomics consortium (CGC) working group for myelodysplastic syndrome, myelodysplastic/myeloproliferative and myeloproliferative n

  2018cites this paper
• PRR14L mutations are associated with chromosome 22 acquired uniparental disomy, age related clonal hematopoiesis and myeloid neoplasia

  2018cites this paper
• Poor prognosis of chromosome 7 clonal aberrations in Philadelphia-negative metaphases and relevance of potential underlying myelodysplastic features in chronic myeloid leukemia

  2018cites this paper
• Gain of function of ASXL1 truncating protein in the pathogenesis of myeloid malignancies.

  2018cites this paper
• Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia

  2017cites this paper
• ASXL1 interacts with the cohesin complex to maintain chromatid separation and gene expression for normal hematopoiesis

  2017cites this paper
• Myeloid Leukemia – Clinical Diagnosis and Treatment 96 2 . Molecular mechanisms of BCR-ABL

  2017cites this paper
• Frequent somatic mutations in epigenetic regulators in newly diagnosed chronic myeloid leukemia

  2017cites this paper
• ASXL1 and JAK2V617F gene mutation screening in Iranian patients with chronic myeloid leukemia

  2017cites this paper
• Chronic Myeloid Leukemia with an e6a2 BCR-ABL1 Fusion Transcript: Cooperating Mutations at Blast Crisis and Molecular Monitoring

  2017cites this paper
• Study of ASXL1 gene mutation in Chronic Myelogenous Leukemia

  2016cites this paper
• Studies to Investigate Epigenetic Factors in Acute Myeloid Leukaemia

  2016cites this paper
• Prognostic significance of ASXL1 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: A meta-analysis

  2016cites this paper
• Resistance to Tyrosine Kinase Inhibitors

  2016cites this paper
• موتاسیون ژن ASXL1 در لوسمی میلوژنوس مزمن

  2016cites this paper
• The Resistance to Tyrosine Kinase Inhibitors in Chronic Myeloid Leukemia: An Overview

  2016cites this paper
• Prognostic significance of SRSF2 mutations in myelodysplastic syndromes and chronic myelomonocytic leukemia: a meta-analysis

  2016cites this paper
• ASXL1 mutation correction by CRISPR/Cas9 restores gene function in leukemia cells and increases survival in mouse xenografts

  2015cites this paper
• Pharmacogénétique de l'Imatinib dans la Leucémie Myéloïde Chronique etDonnées Censurées par Intervalles en présence de Compétition

  2015cites this paper
• A novel mouse model identifies cooperating mutations and therapeutic targets critical for chronic myeloid leukemia progression

  2015influential citation
• Genetic polymorphisms associated with increased risk of developing chronic myelogenous leukemia

  2015cites this paper
• New insights in myeloid malignancies: application of massive genomics approaches for diagnosis and monitoring

  2014cites this paper
• Submicroscopic deletion of 5q involving tumor suppressor genes (CTNNA1, HSPA9) and copy neutral loss of heterozygosity associated with TET2 and EZH2 mutations in a case of MDS with normal chromosome and FISH results

  2014cites this paper
• Molecular-defined clonal evolution in patients with chronic myeloid leukemia independent of the BCR-ABL status

  2014cites this paper
• MYELOID NEOPLASIA Loss of Asxl 1 leads to myelodysplastic syndrome – like disease in mice

  2014cites this paper
• Loss of Asxl1 leads to myelodysplastic syndrome-like disease in mice.

  2014cites this paper
• Acquired ASXL1 mutations are common in patients with inherited GATA2 mutations and correlate with myeloid transformation

  2014cites this paper
• Gene mutations differently impact the prognosis of the myelodysplastic and myeloproliferative classes of chronic myelomonocytic leukemia

  2014cites this paper
• Use of Single Nucleotide Polymorphism Array Technology to Improve the Identification of Chromosomal Lesions in Leukemia

  2013cites this paper
• High imatinib dose overcomes insufficient response associated with ABCG2 haplotype in chronic myelogenous leukemia patients

  2013cites this paper
• Evaluating treatment response of chronic myeloid leukemia: emerging science and technology.

  2013cites this paper
• ASXL1, TP53 and IKZF3 mutations are present in the chronic phase and blast crisis of chronic myeloid leukemia

  2013cites this paper
• Proposal on TO EXPLORE ASSOCIATION OF TGFBR 1 , TGFBR 2 , SMAD 4 AND SMAD 6 GENES WITH CHRONIC MYELOID LEUKEMIA

  2013cites this paper
• Feature-Based Classification of Amino Acid Substitutions outside Conserved Functional Protein Domains

  2013cites this paper
• Mutations in the spliceosome machinery, a novel and ubiquitous pathway in leukemogenesis.

  2012cites this paper
• Update on cytogenetic and molecular changes in myelodysplastic syndromes

  2012cites this paper
• Towards the Cure of CML by the Molecular Approach Strategy

  2012cites this paper
• Two novel patients with Bohring–Opitz syndrome caused by de novo ASXL1 mutations

  2012cites this paper
• Mutations in ASXL 1 are associated with poor prognosis across the spectrum of malignant myeloid diseases

  2012cites this paper
• Transformation of a Chronic Myeloproliferative Neoplasm to Acute Myelogenous Leukemia: Does Anything Work?

  2012cites this paper
• The role of mutations in epigenetic regulators in myeloid malignancies

  2012cites this paper
• Przewlekła białaczka szpikowa jako drugi nowotwór mieloproliferacyjny u pacjentki z wieloletnim przebiegiem pierwotnej mielofibrozy

  2012cites this paper
• Blastic Transformation of BCR-ABL-Negative Myeloproliferative Neoplasms

  2012cites this paper
• Myeloid malignancies: mutations, models and management

  2012cites this paper
• Mutations in ASXL1 are associated with poor prognosis across the spectrum of malignant myeloid diseases

  2012cites this paper
• Microarray analysis of responsible genes in increased growth rate in the subline of HL60 (HL60RG) cells.

  2012cites this paper
• Mutational determinants of epigenetic instablity in myeloid malignancies.

  2012cites this paper
• Different characteristics identified by single nucleotide polymorphism array analysis in leukemia suggest the need for different application strategies depending on disease category

  2012cites this paper
• Genome-wide high density single-nucleotide polymorphism array-based karyotyping improves detection of clonal aberrations including der(9) deletion, but does not predict treatment outcomes after imatinib therapy in chronic myeloid leukemia

  2011cites this paper
• ASXL1 mutations identify a high-risk subgroup of older patients with primary cytogenetically normal AML within the ELN Favorable genetic category.

  2011cites this paper
• ASXL1 (additional sex combs like 1 (Drosophila))

  2011cites this paper
• CBL , CBLB , TET 2 , ASXL 1 , and IDH 1 / 2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia

  2011cites this paper
• 1 CBL , CBLB , TET 2 , ASXL 1 and IDH 1 / 2 Mutations and Additional Chromosomal Aberrations Constitute Molecular Events in Chronic Myelogenous Leukemia

  2011cites this paper
• Genetics of the myeloproliferative neoplasms

  2011cites this paper
• Prognostic significance of ASXL1 mutations in patients with myelodysplastic syndromes.

  2011cites this paper
• Lysine methylation of promoter-bound transcription factors and relevance to cancer

  2011cites this paper
• Selection of therapy: rational decisions based on molecular events.

  2011cites this paper
• CBL, CBLB, TET2, ASXL1, and IDH1/2 mutations and additional chromosomal aberrations constitute molecular events in chronic myelogenous leukemia.

  2011cites this paper
• Disruption of the ASXL1 gene is frequent in primary, post-essential thrombocytosis and post-polycythemia vera myelofibrosis, but not essential thrombocytosis or polycythemia vera: analysis of molecular genetics and clinical phenotypes

  2011cites this paper
• Mutation analysis of TET2, IDH1, IDH2 and ASXL1 in chronic myeloid leukemia

  2011cites this paper
• Mutations with epigenetic effects in myeloproliferative neoplasms and recent progress in treatment: Proceedings from the 5th International Post-ASH Symposium

  2011cites this paper
• The most commonly reported variant in ASXL1 (c.1934dupG;p.Gly646TrpfsX12) is not a somatic alteration

  2010cites this paper
• Concomitant analysis of EZH2 and ASXL1 mutations in myelofibrosis, chronic myelomonocytic leukemia and blast-phase myeloproliferative neoplasms

  2010cites this paper
• Open letter to the Editor

  2010cites this paper
• Genetic typing of CBL, ASXL1, RUNX1, TET2 and JAK2 in juvenile myelomonocytic leukaemia reveals a genetic profile distinct from chronic myelomonocytic leukaemia

  2010influential citation
• ASXL1 mutation is associated with poor prognosis and acute transformation in chronic myelomonocytic leukaemia

  2010influential citation
• Recherche de nouvelles cibles moléculaires dans les syndromes myélodysplasiques et leucémies aiguës myéloïdes

  2010cites this paper